Miro1 linked to muscle insulin resistance in type 2 diabetes

Researchers investigated Miro1, a protein on the outer membrane of mitochondria, as a possible contributor to skeletal-muscle insulin resistance. The study combined laboratory cell work, preclinical models and research involving people with type 2 diabetes. The supplied report does not give participant numbers or detailed trial methods.

Miro1 levels were higher in the skeletal muscles of people with type 2 diabetes. In preclinical models, removing Miro1 restored muscle responsiveness to insulin. In a randomized trial among participants with obesity and type 2 diabetes, those assigned to aerobic exercise had lower muscle Miro1 levels, alongside improvements in insulin sensitivity and muscle energy-production capacity; the comparator was standard medical care.

The findings identify a possible mechanism linking Miro1 to insulin resistance and suggest a direction for further therapeutic research. However, direct Miro1-targeting treatment was not tested in people: causal restoration of insulin responsiveness was shown in preclinical models, while the human findings concerned exercise-associated changes. The report provides no sample size or quantitative effect estimates, limiting assessment of the clinical evidence.